ISOTECHNIKA REPORTS RESULTS OF PSORIASIS TRIAL

A A

Isotechnika has reported that preliminary data show continued efficacy and safety in a Phase III psoriasis trial of its lead drug.

Patients receiving higher doses from the start showed improvements of 61 to 66 per cent. There were 101 patients who dropped out of the study, 15 because of adverse reactions, one of them serious.